Orelabrutinib: First Approval

被引：105
作者：
Dhillon, Sohita [1 ]
机构：
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS | 2021年 / 81卷 / 04期
关键词：
INHIBITORS;
D O I：
10.1007/s40265-021-01482-5
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Dysregulation of Bruton's tyrosine kinase (BTK) signalling has been linked to various B cell malignancies and autoimmune diseases. Orelabrutinib (<SIC>(R)) is an orally administered, potent, irreversible and highly selective BTK-inhibitor being developed by InnoCare Pharma for the treatment of B cell malignancies and autoimmune diseases. In December 2020, orelabrutinib received its first approval in China for the treatment of patients with mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL), who have received at least one treatment in the past. Clinical development of orelabrutinib for various indications is underway in the USA and China. This article summarizes the milestones in the development of orelabrutinib leading to this first approval.
引用
收藏
页码：503 / 507
页数：5
相关论文
共 12 条
[1]  
InnoCare Pharma Ltd, 2021, OR CHIN PRECR INF
[2]  
Li Z, BLOOD, V134, P4319
[3]   Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE? [J].
Lorenzo-Vizcaya, Ana ;
Fasano, Serena ;
Isenberg, David A. .
IMMUNOTARGETS AND THERAPY, 2020, 9 :105-110
[4]  
NMPA China, 2021, OR TABL
[5]  
Shaw Maggie L, 2020, Am J Manag Care, V26, pSP226, DOI 10.37765/ajmc.2020.88475
[6]   Role of Bruton's tyrosine kinase in B cells and malignancies [J].
Singh, Simar Pal ;
Dammeijer, Floris ;
Hendriks, Rudi W. .
MOLECULAR CANCER, 2018, 17
[7]   Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies [J].
Song, Yuqin ;
Xu, Wei ;
Song, Yongping ;
Liu, Lihong ;
Lin, Song ;
Li, Zhiming ;
Liu, Ting ;
Yi, Shuhua ;
Zhou, Daobin ;
Zhang, Mingzhi ;
Hu, Yu ;
Jin, Jie ;
Zhu, Huaqiang ;
Lu, Zhengguang ;
Zhao, Renbin ;
Xu, Zhixin ;
Zhu, Jun .
BLOOD, 2020, 136
[8]   Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study [J].
Song, Yuqin ;
Song, Yongping ;
Liu, Lihong ;
Zhang, Mingzhi ;
Li, Zhiming ;
Ji, Chunyan ;
Xu, Wei ;
Liu, Ting ;
Xu, Bing ;
Wang, Xin ;
Gao, Sujun ;
Zhang, Huilai ;
Hu, Yu ;
Li, Yan ;
Cheng, Ying ;
Yang, Haiyan ;
Cao, Junning ;
Zhu, Zunmin ;
Hu, Jianda ;
Zhang, Wei ;
Jing, Hongmei ;
Ding, Kaiyang ;
Lu, Zhengguang ;
Zhang, Bin ;
Zhao, Renbin ;
Xu, Zhixin ;
Zhu, Jun .
BLOOD, 2019, 134
[9]   Inhibitors of BTK and ITK: State of the New Drugs for Cancer, Autoimmunity and Inflammatory Diseases [J].
Vargas, L. ;
Hamasy, A. ;
Nore, B. F. ;
Smith, C. I. E. .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2013, 78 (02) :130-139
[10]   Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia [J].
Xu, Wei ;
Song, Yongping ;
Wang, Tingyu ;
Yang, Shenmiao ;
Liu, Lihong ;
Hu, Yu ;
Zhang, Wei ;
Zhou, Jianfeng ;
Gao, Sujun ;
Ding, Kaiyang ;
Zhang, Huilai ;
Zhu, Zunmin ;
Wang, Shun-Qing ;
Xu, Bing ;
Hu, Jianda ;
Liu, Ting ;
Ji, Chunyan ;
Xia, Zhongjun ;
Li, Yan ;
Wang, Xin ;
Zhu, Huaqiang ;
Zhao, Renbin ;
Zhang, Bin ;
Xu, Zhixin ;
Li, Jianyong .
BLOOD, 2020, 136
12